TERC and myeloid sarcoma: TERC rs35073794 was associated with about 3.4-fold decreased odds of subjects younger than 44 years of age developing MS according to the dominant, overdominant, and additive models (OR: 0.295, (95% CI: 0.173–0.503), p < 0.001; OR: 0.295 (95% CI: 0.173–0.503), p < 0.001; OR: 0.295 (95% CI: 0.173–0.503), p < 0.001, respectively).